BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada.

On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system.

Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms.

If you’re looking for a pharma name with solid prospects you should be checking out Canadian company BioSyent. Portfolio manager Jason Del Vicario of Hillside Wealth Management says their new drug could be a big money-maker.

In a nutshell, we believe at current prices, markets are ignoring growth guided by the management. We feel BioSyent's strong financials, previous operational execution, and management's skin in the game makes it a buy.

GNM speaks with Dr. Hance Clarke about the benefits and risks to the newly approved acute pain drug.

Nardine Nakhla, University of Waterloo professor and community pharmacist discusses Combogesic® for acute pain management in the Pharmacy Practice + Business journal.